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Introduction
Phenobarbital and "phenobarbital-like" chemicals induce the transcription of CYP2B and other genes by activating CAR [see (Kodama and Negishi, 2006) for recent review]. We previously reported that treatment of rats or primary cultured rat hepatocytes with squalestatin 1 (also known as zaragozic acid A), an inhibitor of squalene synthase, the first committed step in cholesterol biosynthesis, caused the selective induction of CYP2B (Kocarek, et al., 1998) , relative to other inducible P450s, and that this induction was attributable to squalene synthase inhibition and the accumulation of an endogenous isoprenoid(s) that is capable of activating CAR (Kocarek and Mercer-Haines, 2002 ) (see Fig. 1 for scheme of the isoprenoid pathway).
In continuation of this investigation, we sought to determine whether squalestatin 1-mediated CYP2B induction was strictly dependent upon the biosynthesis of FPP, the substrate for squalene synthase. FPP is formed through the FDPS-catalyzed condensation of one molecule of GPP with one molecule of IPP. In addition to its role as a sterol precursor, FPP is a branchpoint intermediate that is metabolized by several other enzymes, including protein farnesyl transferase, which catalyzes the farnesylation of certain proteins, such as small GTPases (Basso, et al., 2006) ; GGPP synthase, which catalyzes the formation of GGPP (Kavanagh, et al., 2006) , which is also utilized in protein prenylation reactions (Basso, et al., 2006) ; trans-prenyltransferase, which leads to the biosynthesis of ubiquinone (although in mammals, GPP is this enzyme's preferred substrate) (Dallner and Sindelar, 2000) ; cis-prenyltransferase, which leads to the formation of dolichol and dolichyl phosphate (Krag, 1998) (Brown, et al., 2002) . In addition, FPP can be dephosphorylated to farnesol by one or more lipid phosphatases that
have not yet been formally identified (Bansal and Vaidya, 1994) , although recombinant human phosphatidic acid phosphatase 2a (PAP2a) has been shown to be capable of catalyzing this reaction in vitro (Fukunaga, et al., 2006) . Farnesol can then be sequentially oxidized to farnesal, farnesoic acid and a family of dioic acids that are excreted in large quantities by animals treated with squalestatin 1 (Vaidya, et al., 1998; Bostedor, et al., 1997) .
Alendronate is an NBP that inhibits FDPS with nanomolar potency (Keller and Fliesler, 1999; Bergstrom, et al., 2000) . Alendronate and other drugs of its class, including risedronate and zoledronate, are used clinically for the prevention and treatment of osteoporosis, and this therapeutic efficacy is thought to be the result of FDPS inhibition, which decreases the availability of FPP and GGPP for protein prenylation reactions, which in turn leads to activation of osteoclast apoptosis (Russell, et al., 2007) .
Because FDPS not only catalyzes the formation of FPP, but also catalyzes the preceding metabolic reaction in which IPP and DMAPP condense to form GPP, alendronate treatment causes the accumulation of IPP and DMAPP (Keller and Fliesler, 1999; Bergstrom, et al., 2000) .
In this study, we used alendronate to test whether squalestatin 1-mediated CYP2B induction in primary cultured rat hepatocytes is dependent upon the production of FPP.
We report not only that squalestatin 1-mediated CYP2B induction is effectively abolished by alendronate treatment, but also that phenobarbital-mediated CYP2B induction is This article has not been copyedited and formatted. The final version may differ from this version. Primary culture of rat hepatocytes. Hepatocytes were isolated from adult male Sprague-Dawley rats (250-350 g, Harlan, Indianapolis, IN) as previously described (Kocarek and Reddy, 1996) . Freshly isolated hepatocytes were suspended in Williams'
Medium E supplemented with 0.25 U/ml insulin, 10 -7 M triamcinolone acetonide, 100u/ml penicillin and 100ug/ml streptomycin and plated into collagen (PureCol; 99.9% collagen; ~97% type I collagen with remainder type III collagen)-coated plastic vessels.
Three million viable hepatocytes were plated into 60-mm dishes (for FPP measurements This article has not been copyedited and formatted. The final version may differ from this version. at 24 hr intervals. Drug treatments were initiated 48 hr post-plating, and were performed as described in the individual figure legends. Drugs were added to the culture medium as concentrated stock solutions in water.
Northern and western blot analysis. Total RNA was isolated from hepatocytes cultured in 6-well plates using TRIzol Reagent (Invitrogen), and the RNA samples constituting each treatment group (3 wells of hepatocytes per group) were pooled. Ten µg samples of RNA were resolved on denaturing agarose gels and analyzed by northern blot hybridization, using the procedures and cDNA probes to CYP2B1, CYP3A23, HMGCoA reductase and 7S that have been described previously (Kocarek and Reddy, 1996) .
Because the CYP2B1 and CYP3A23 cDNA probes cross-react with multiple related transcripts, the bands detected with these probes are referred to as CYP2B and CYP3A. Tris-HCl 12-well Ready-Gels (BioRad) and 2 µg microsomal protein per well, and resolved proteins were transferred onto Immuno-Blot PVDF membranes (BioRad).
Immunoreactive CYP2B proteins were detected using a polyclonal antibody to CYP2B1 Measurement of FPP levels. Cellular levels of FPP were measured according to the method described by Tong et al. (Tong, et al., 2005) . Following treatment, hepatocytes were recovered from 60 mm dishes using Cell Recovery Solution, as described above.
The hepatocytes constituting each treatment group (three dishes of hepatocytes per group) were pooled. Cellular protein contents were measured using the bicinchoninic acid assay (Smith, et al., 1985) . Cell pellets were extracted twice at 70°C with butanol-75 mM ammonium hydroxide-ethanol (1:1.25:2.75 v/v/v). Pooled supernatants were dried under nitrogen at 50°C and residues were dissolved in 50 mM Tris-HCl, pH 7. Chromatography was performed at room temperature with a mobile phase flow rate of 1 ml/min, and was initiated upon sample injection with 38% B for 1 min, followed by linear transition over 7 min to 100% B, followed by 100% B for 8 min, followed by return to initial conditions over 3 min, followed by re-equilibration. The free and farnesylated peptides were detected using an excitation wavelength of 335 nm and an emission wavelength of 528 nm. The retention time for the farnesylated peptide varied from 5.5 to 6.4 minutes, depending on the ambient temperature. Peak areas were determined, and data were calculated as pmol FPP per mg cellular protein.
This article has not been copyedited and formatted. The final version may differ from this version. 
Results
Initial experiments were performed to determine the ability of alendronate to produce effective inhibition of FDPS activity in primary cultured rat hepatocytes, using cellular FPP content as the criterion. Because untreated primary rat hepatocyte cultures contained very low levels of FPP, and treatment with 0.1 μM squalestatin 1 caused substantial FPP accumulation (10-to 20-fold, data not shown), the concentrationdependent ability of alendronate to reduce squalestatin 1-mediated FPP accumulation was evaluated. Treatment of rat hepatocyte cultures with alendronate concentrations lower than 10 μM had no effect on squalestatin 1-mediated FPP accumulation (data not shown), but treatment with alendronate concentrations of 10 to 100 μ M produced a concentrationdependent reduction of FPP levels (IC 50 ~40 μ M), with average decreases of ~75% and >90% occurring at alendronate concentrations of 60 and 100 μ M, respectively ( Fig. 2A) .
These effective alendronate concentrations were not toxic to the hepatocytes, as judged by the lack of effect on MTT activity (Fig. 2B) . Alendronate was next evaluated for its ability to modify CYP2B, CYP3A and HMG-CoA reductase expression, either when used alone or in combination with 0.1 μ M squalestatin 1 or 100 μ M phenobarbital (Fig.   3 ). Treatment with alendronate alone had no effect on CYP2B or CYP3A mRNA content (Fig. 3) . However, co-treatment with alendronate effectively inhibited squalestatin 1-mediated CYP2B induction (IC 50~3 0 μ M), with complete suppression occurring at alendronate concentrations of 60 and 100 μ M (Fig. 3) . In addition, alendronate treatment produced a concentration-dependent suppression of phenobarbital-mediated CYP2B induction, which, although, less pronounced than the absolute blockade that occurred for This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 3) . Although phenobarbital is commonly regarded as an inducer of both CYP2B and CYP3A, this drug induces CYP2B and CYP3A with different concentration-dependencies (Kocarek, et al., 1990) . Thus, while maximal CYP2B induction is achieved at 100 µM phenobarbital, this concentration produces only a slight elevation of CYP3A expression. Alendronate co-treatment suppressed the phenobarbital-mediated CYP3A induction that did occur in parallel with the abovedescribed suppression of CYP2B induction (Fig. 3) . As an additional observation, squalestatin 1 treatment produced the expected up-regulation of HMG-CoA reductase expression that signifies effective blockade of cholesterol biosynthesis (Fig. 3) . By contrast, treatment with alendronate produced only very slight up-regulation of HMGCoA reductase expression, even at a concentration (100 μ M) that produced near complete inhibition of farnesyl diphosphate synthase (Figs 2 and 3) . Moreover, alendronate cotreatment produced a concentration-dependent suppression of the squalestatin 1-mediated HMG-CoA reductase up-regulation that was in close correspondence to alendronate's suppressive effects on phenobarbital-inducible CYP2B and CYP3A expression (Fig. 3) .
The partial suppression of phenobarbital-mediated CYP2B induction that was produced by alendronate co-treatment prompted us to consider whether the effect was produced by alendronate itself, or rather was a consequence of FDPS inhibition, as NBP treatments have been reported to cause accumulation of upstream isoprenoids, including isopentenyl pyrophosphate and dimethylallyl pyrophosphate (Keller and Fliesler, 1999; Bergstrom, et al., 2000) . To discriminate between these possibilities, we performed treatments with the HMG-CoA reductase inhibitor, pravastatin, to shut off the cholesterol This article has not been copyedited and formatted. The final version may differ from this version. (Kocarek and Reddy, 1996; Kocarek, et al., 2002) . The concentration-dependent ability of alendronate to suppress phenobarbital-mediated CYP2B induction was evaluated in the absence and presence of pravastatin (Fig. 4A) . As previously seen, alendronate treatment produced concentration-dependent suppression of phenobarbital-mediated CYP2B
induction. This suppression was attenuated when the hepatocytes were co-treated with pravastatin. In particular, the suppressive effect that was produced by 60 μ M alendronate was largely prevented by pravastatin co-treatment, while the greater suppression that was produced by 100 μ M alendronate treatment was partially reversed by pravastatin (Fig.   4A ). Next, the effects of pravastatin-mediated HMG-CoA reductase blockade, combined with rescue by mevalonate treatment, were evaluated on alendronate (60 μ M)-mediated suppression of phenobarbital-inducible CYP2B mRNA and immunoreactive protein levels ( Fig. 4B ) and CYP2B-mediated catalytic activity (Fig. 4C) . Alendronate-mediated suppression of phenobarbital-inducible CYP2B expression was evident at all levels of measurement, as was pravastatin-mediated reversal of the suppression. Co-treatment of pravastatin-treated hepatocyte cultures with mevalonate restored alendronate's ability to cause suppression of phenobarbital-mediated CYP2B induction ( Fig. 4B and C) .
Squalestatin 1-mediated induction of CYP2B mRNA, protein and enzymatic activity was abolished by treatment with 60 μ M alendronate ( Fig. 4B and C) .
Discussion
Alendronate treatment alone had no effect on CYP2B or CYP3A mRNA expression in primary cultured rat hepatocytes, but completely suppressed squalestatin 1-inducible CYP2B expression at the same concentrations that inhibited FDPS. Although, given alendronate's reported nanomolar potency for FPDS inhibition in vitro (Keller and Fliesler, 1999; Bergstrom, et al., 2000) , the alendronate concentrations (10-100 μ M) that caused effective FPDS inhibition in cultured rat hepatocytes may seem high, these concentrations are comparable to those found to produce FPDS inhibition in cultured murine osteoclasts (Bergstrom, et al., 2000) . The complete blockade of squalestatin 1-mediated CYP2B induction that was produced by alendronate treatment is consistent with a requirement for ongoing FPP synthesis in the induction process, although a caveat is that FDPS inhibition prevents the production of both GPP and FPP. Nevertheless, these findings clearly demonstrate that squalestatin 1 is incapable of causing CYP2B induction unless isoprenoid biosynthesis is allowed to proceed at least to the level of GPP.
Phenobarbital was included in this study as a positive control CAR activator and CYP2B inducer, whose effect on CYP2B expression is unaffected by co-treatment with the upstream cholesterol biosynthesis inhibitor, pravastatin (Kocarek and Mercer-Haines, 2002 ). Our expectation was that phenobarbital-mediated CYP2B induction, in contrast to squalestatin 1-mediated induction, would be unaltered by alendronate co-treatment.
However, alendronate treatment was found to produce a concentration-dependent suppression of phenobarbital-mediated CYP2B induction that, while less pronounced than the complete blockade of squalestatin 1-mediated induction that occurred, was isoprenoid, biosynthesis, attenuated the ability of alendronate to suppress phenobarbitalinducible CYP2B expression, and this attenuation was overridden by bypassing the pravastatin-mediated blockade through the addition of exogenous mevalonate.
Pravastatin treatment effectively reversed the suppressive effect on phenobarbitalmediated CYP2B expression that was produced by 60 μ M alendronate, but only partially reversed the larger suppressive effect that was produced by 100 μ M alendronate. These findings indicate that alendronate's suppressive effects on phenobarbital-mediated CYP2B induction can be attributed both to FDPS inhibition with upstream metabolite accumulation (i.e., since some of the effect can be reversed by upstream blockade) and to direct drug action on the induction process (i.e., since some of the effect is not inhibited by pravastatin treatment).
The nature of the alendronate-generated endogenous bioactive suppressor of phenobarbital-mediated CYP2B induction can be surmised by the knowledge that alendronate treatment has been shown to cause accumulation of the upstream isoprenoids, IPP and DMAPP (Keller and Fliesler, 1999; Bergstrom, et al., 2000) . 18 inflammatory cytokines in a manner that can be prevented by statin treatment and mimicked by IPP or DMAPP (Tanaka, et al., 1995; Burk, et al., 1995; Kunzmann, et al., 2000; Thompson and Rogers, 2004; Hewitt, et al., 2005) . It has been suggested that this action may underlie the rare occurrence of musculoskeletal adverse effects that occur in patients taking NBPs (Bock, et al., 2007) . IPP has also been identified as a tumor cell antigen that causes activation of VγVδ2 T-cells (Gober, et al., 2003) , which has implications for the mechanisms governing immunosurveillance in response to the metabolic derangements occurring in cancer cells. NBPs also cause necrotic and inflammatory effects in rats and mice, although these species lack VγVδ2 T-cells, and IPP also appears to underlie at least some of these effects (Deng, et al., 2007) . Such inflammatory effects could conceivably confound investigation of the ability of NBP treatment to modify hepatic P450 regulation in vivo.
Second, IPP is able to combine with adenosine monophosphate, in a reaction catalyzed by aminoacyl-tRNA synthases, to form a novel ATP analog, termed triphosphoric acid 1-adenosin-5'-yl ester 3-(3-methylbut-3-enyl) ester, or ApppI (Monkkonen, et al., 2006) . ApppI has been identified in extracts of cultured osteoclasts, macrophages and glioma cells treated with an NBP (Monkkonen, et al., 2006) , as well as in peritoneal macrophages isolated from zoledronate-treated mice (Monkkonen, et al., 2007) . ApppI has been shown to induce apoptosis in osteoclast cells as a result of inhibition of the mitochondrial adenine nucleotide translocase (Monkkonen, et al., 2006) .
Therefore, NBP-mediated osteoclast apoptosis is likely the result of two mechanisms acting in combination: i.e., reduction of FPP and GGPP levels, which reduces the This article has not been copyedited and formatted. The final version may differ from this version. Whether or how either of the two above-described actions may contribute to the alendronate-mediated suppressive effects on CYP2B induction that we report in this study is a topic for further investigation. Since current evidence suggests that CAR can be activated by processes that cause activation of the energy-sensing AMP-activated protein kinase (Rencurel, et al., 2005; Rencurel, et al., 2006; Shindo, et al., 2007; Blattler, et al., 2007) , it seems possible that ApppI formation, followed by inhibition of adenine nucleotide translocase and alteration of hepatocellular ATP/AMP balance may contribute to the mechanism whereby alendronate treatment causes suppression of phenobarbitalinducible CYP2B expression. An additional possibility is that alendronate and/or one or more of the upstream isoprenoids are able to interact with CAR as inverse agonists.
However, our initial experiments, using an in vitro human CAR interaction assay, have not supported the operation of such a suppressive mechanism.
It is clear that endogenous isoprenoids are capable of producing diverse effects on hepatic P450 expression. Achieving an understanding of the underlying mechanisms will both enhance our knowledge about the biological capacity of this complex series of endogenous molecules and improve our ability to predict the impact of isoprenoidmodifying treatments on xenobiotic metabolism.
